Point72 Asset Management L.P. maintained its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the first quarter, according to its most recent disclosure with the SEC. The firm owned 310,179 shares of the biopharmaceutical company’s stock at the end of the first quarter. Point72 Asset Management L.P. owned approximately 1.73% of Xenon Pharmaceuticals worth $1,241,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in the company. Renaissance Technologies LLC raised its stake in shares of Xenon Pharmaceuticals by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 114,200 shares of the biopharmaceutical company’s stock worth $879,000 after buying an additional 18,000 shares in the last quarter. K2 Principal Fund L.P. raised its stake in shares of Xenon Pharmaceuticals by 104.4% in the first quarter. K2 Principal Fund L.P. now owns 116,975 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 59,747 shares in the last quarter. KCG Holdings Inc. acquired a new stake in shares of Xenon Pharmaceuticals during the first quarter worth approximately $122,000. Sabby Management LLC acquired a new stake in shares of Xenon Pharmaceuticals during the first quarter worth approximately $1,186,000. Finally, Endurant Capital Management LP purchased a new stake in Xenon Pharmaceuticals during the first quarter valued at about $1,363,000. 56.01% of the stock is currently owned by institutional investors and hedge funds.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) traded up 1.52% during trading on Friday, hitting $3.35. 12,434 shares of the company traded hands. The stock has a 50 day moving average price of $3.60 and a 200 day moving average price of $5.63. The company’s market capitalization is $60.29 million. Xenon Pharmaceuticals Inc. has a 12-month low of $2.85 and a 12-month high of $9.95.
ILLEGAL ACTIVITY NOTICE: “Xenon Pharmaceuticals Inc. (XENE) Stake Held by Point72 Asset Management L.P.” was published by BBNS and is owned by of BBNS. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://baseballnewssource.com/markets/xenon-pharmaceuticals-inc-xene-stake-held-by-point72-asset-management-l-p-updated/1180414.html.
Several research firms have issued reports on XENE. Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, July 1st. Jefferies Group LLC dropped their price target on shares of Xenon Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, June 28th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $5.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday, June 27th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Xenon Pharmaceuticals has an average rating of “Buy” and an average price target of $11.88.
In other news, insider Value Fund L. P. Biotechnology acquired 85,461 shares of the stock in a transaction that occurred on Tuesday, June 27th. The shares were acquired at an average cost of $4.00 per share, for a total transaction of $341,844.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Value Fund L. P. Biotechnology acquired 20,411 shares of the stock in a transaction that occurred on Thursday, June 22nd. The stock was purchased at an average price of $4.00 per share, for a total transaction of $81,644.00. The disclosure for this purchase can be found here. Insiders purchased a total of 490,978 shares of company stock worth $1,891,534 over the last 90 days. 9.40% of the stock is currently owned by company insiders.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.